Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gardasil Vaccine Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

NCT06623409
View directory record Official record
Conditions
Healthy
Interventions
GARDASIL®9 (G9), V540B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
5
States / cities
Anaheim, California • Glendale, California • Hallandale, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Not yet recruiting Phase 2 Interventional

Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT07756840
View directory record Official record
Conditions
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases, Tracheal Diseases, Respiratory Tract Neoplasm
Interventions
PRGN-2012, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video to Promote HPV Vaccination

NCT02196454
View directory record Official record
Conditions
Vaccine Acceptance, Social Acceptance, Acceptance Processes, Health Behavior, Human Papillomavirus
Interventions
Educational Video with Male or Female Narrator
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Flourtown, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 4, 2026, 3:01 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

NCT04206813
View directory record Official record
Conditions
HPV Infection
Interventions
Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Not applicable Interventional Results available

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

NCT00806676
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Gardasil® Vaccine (FDA-approved vaccination regimen)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 4, 2026, 3:01 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

NCT01290393
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 4 Interventional Results available

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

NCT01034358
View directory record Official record
Conditions
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

NCT03943875
View directory record Official record
Conditions
Immunization, Efficacy, Human Papilloma Virus
Interventions
9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
15 Years to 26 Years
Enrollment
767 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 4, 2026, 3:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescent Vaccination in Pharmacies

NCT01960088
View directory record Official record
Conditions
Evaluating Attitudes Toward HPV Vaccinations in Pharmacies, Evaluating the Provision of HPV Vaccines in a Pharmacy
Interventions
HPV vaccine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 18 Years
Enrollment
1,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 4, 2026, 3:01 AM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 4, 2026, 3:01 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

NCT05985681
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

NCT01343485
View directory record Official record
Conditions
GARDASIL Vaccination
Interventions
Computer reminder system
Behavioral
Lead sponsor
Planned Parenthood Federation of America
Other
Eligibility
19 Years to 26 Years · Female only
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Glendale, Arizona • Arvada, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 4, 2026, 3:01 AM EDT
Completed Not applicable Interventional Results available

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

NCT00786409
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Gardasil
Biological
Lead sponsor
University of Chicago
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 4, 2026, 3:01 AM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 3:01 AM EDT